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Lyme disease (LD) is the most common tick-borne disease in the northern hemisphere,
producing a wide range of disabling effects on multiple human targets, including the skin, the
nervous system, the joints and the heart. Insufficient clinical diagnostic methods, the necessity
for prompt antibiotic treatment along with the pervasive nature of infection impel the
development and establishment of new clinical diagnostic tools with increased accuracy,
sensitivity and specificity. The goal of this article is 4-fold: (i) to detail LD infection and
pathology, (ii) to review prevalent diagnostic methods, emphasizing inherent problems, (iii) to
introduce the usage of in vivo induced antigen technology (IVIAT) in clinical diagnostics and
(iv) to underscore the relevance of a novel comprehensive LD diagnostic approach to
practitioners of Complementary and Alternative Medicine (CAM). Utilization of this analytical
method will increase the accuracy of the diagnostic process and abridge the time to treatment,
with antibiotics, herbal medicines and nutritional supplements, resulting in improved quality of
care and disease prognosis.
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Introduction
Bacterial infection with specific spirochetes from the
genus Borrelia, usually acquired from the bite of an
infected Ixodes tick, is the cause of Lyme disease (LD).
The species complex B. burgdorferi sensu stricto is
predominantly responsible for LD cases in the United
States while B. burgdorferi sensu lato, B. afzelii and
B. garinii are the responsible pathogenic species in
Europe and Asia (1,2).
Presentation and destructive effects of LD vary widely
depending on the stage and magnitude of spirochete
dissemination. Initial effects may include rashes or
flu-like symptoms, while later stages may be characterized
by arthritic, neurological, psychiatric and cardiac
symptoms.
Due to the varying nature of symptom appearance
there exist a number of DNA technologies and sero-
logical methods that may be utilized, in conjunction with
clinical examination, to support and confirm a diagnosis
of LD; however, the techniques maintain certain
pitfalls. Divergent symptoms between infected individuals
and flawed clinical diagnostics hinder accurate diagnosis
and prompt antibiotic treatment, which are essential
for a good prognosis and the prevention of chronic
infection (3).
The conventional treatment for LD is a course of
antibiotic therapy, such as doxycycline, amoxicillin,
penicillin, erythromycin and other antibiotics listed
in Table 1. Maximal efficacy of oral antibiotic adminis-
tration is rendered in the early stages of infection,
typically days or weeks following pathogen introduction.
At the chronic stage of the disease, administration of
a combination of these medications orally, intramuscu-
larly and intravenously is required for several months
before an attenuation of infection is apparent (4–8).
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properly cited.The swiftness in diagnosis is further emphasized by the
characteristic abilities of Borrelia, via antigenic changes
on its surface, to avoid the immune system and
subsequently infiltrate areas of the body maintaining
low levels of drug distribution, such as the joints and
nervous system. Due to this complexity, Complementary
and Alternative Medicine (CAM) holds great promise for
the abrogation of disease pathology through the combi-
nation and utilization of accurate diagnostic methods and
effective treatment modalities (9–30).
The CAM treatment for LD, summarized in Table 1,
combines intravenous antibiotic therapy, herbal medicine
administration and nutritional medicine to enhance the
immune system’s ability to fight this intracellular micro-
organism (9–30).
Considering the side effects of antibiotics and the
length of this treatment with CAM modalities, an
effective procedure for diagnosis of LD is needed to
justify such a course. A novel diagnostic approach to LD,
utilizing in vivo induced antigen technology (IVIAT) and
enzyme-linked immunosorbent assay (ELISA), may
provide the data necessary to justify CAM treatment of
LD and associated spirochetes. Therefore, it is imperative
to review the merit of this diagnostic approach, which
will expedite the accurate diagnosis of LD, in order to
emphasize its importance to practitioners of CAM in
areas of the world greatly affected by LD (31–34).
Prevalent Diagnostic Techniques:
The Benefits and Inherent Drawbacks
A number of diagnostic tests for LD aim to detect the
presence of Borrelia antigens and related immune system
components (35–39). While the theory behind the
development of these techniques was sound, these tests
suffer from false results (40); recent research has served
to give an understanding as to the reasons underlying
such inaccuracies.
Polymerase chain reaction (PCR) for LD attempts to
detect the DNA of the spirochete. In a recent study,
urine-based PCR for LD was evaluated and shown to be
insufficient for a diagnosis (35).
The Center for Disease Control (CDC) proposes a two-
tiered approach to LD diagnosis (36). This includes an
initial screening test such as ELISA with high sensitivity,
which is followed by an immunoblot with high specificity.
ELISA and Initial Screening Test for LD
The Lyme ELISA test is intended for the quantitative
detection of IgG and IgM antibodies to B. burgdorferi in
human serum. Titers of IgG are generally low during the
first weeks of illness. They peak within three to six weeks
after onset but are often not detectable in symptomatic
patients (37). This assay is performed based on crude
Table 1. CAM treatment of Lyme disease with a combination of different antibiotics, herbal remedies, and nutritional supplements, with pertinent
references
Antibiotics used for treatment of
Lyme disease (Refs 6–8, 10, 11)
Herbal remedies Ref Nutritional supplements Ref
Doxycycline Samento (24) Omega-3 Fatty Acids (26)
Minocycline Cumada (24) Coenzyme-Q10 (26)
Amoxicillin Burbur (24) S-Adenosylmethionine (8, 24, 25)
Augmentin Allicin (25) Grapeseed Extract (26)
Azithromycin Dragon’s blood (25) Magnesium (24)
Biaxin Cat’s claw (25) L-Carnitine (4, 8)
Erythromycin Devil’s claw (24) a-Lipoic acid (14, 15)
Vaucomycin Echinacea (25–28) Dimethylglycine (27)
Clarithromycin (biaxin) Citriodiol
(lemon eucalyptus extract)
(9) Vitamin B-complex (4, 8)
Cefuroxime axetil Astragallus (29) Methylcobalamin (4, 8)
Penicillin Nettle (24) Vitamin C and D (12, 13)
Ceftriaxone Ginkgo biloba (4, 8) Hydrolytic enzymes (16, 17)
Rifampin Curcumin (19–20) Mushroom extracts and Beta-glucan (22)
Flagyl Oregano tea (25) Thymic peptides (29)
Plaquenil Boswellia (26) Pycnogenol (27)
Taurox SB
TM Parsley extract (24) N-Acetylcysteine and glutathione (26)
Colloidal silver Red chili pepper (capsaicin) (18) Probiotics (23)
Imipinem Quercetin (21) Dehydroepiandrosterone (12)
Royal Jelly (26)
284 Novel diagnosis of Lyme diseasepreparation of B. burgdorferi in culture and its binding to
solid phase matrix. IgG and IgM antibodies in patients
serum binds specifically to antigen coated wells resulting
in color development. The intensity of color is equivalent
to the level of antibodies.
Western Immunoblot Assay for Confirmation of LD
The western blot assay has been widely used to detect the
presence of antibodies in human serum and plasma to
various infectious disease agents. In this procedure,
component proteins of purified, inactivated bacteria
are electrophoretically separated by SDS-polyacrylamide
electrophoresis followed by electrotransfer to nitrocellu-
lose sheets (38). Each strip served as the solid-phase
antigen for an ELISA test. The western blot assay is
more reliable since the cross-reactive antibodies are
excluded and peptide specific antibodies are observed.
However, if antibodies are not present in the blood, false
negative results will be obtained (39).
Drawbacks of Serodiagnosis of LD
The current problems with serodiagnosis of LD include a
lack of standardization and poor evaluation criteria
regarding sensitivity and specificity. These troubles are
due in part to the broad heterogeneity of the immuno-
dominant antigens from disease causing Borrelia strains
and the utilization of a single strain in the whole-cell
lysate immunoblot assay (36). It is thought that the
usage of several strains of different species would increase
assay sensitivity; while the usage of multiple Borrelia
species grown in culture does provide a broader set of
antigens, it is not sufficient due to antigenic variations
and expression employed by Borrelia to avoid immune
destruction in the mammalian system (40–43). Therefore,
it is crucial to combine clinical symptomology with
sensitive techniques such as IVIAT Multi-Peptide ELISA
that take into account antigenic variation.
In Vivo Included Antigen Technology:
The Key to Enhanced Specificity
IVIAT is a technique that identifies pathogen antigens
that are immunogenic and expressed in vivo during
human infection. Regulating gene expression optimizes
a pathogen’s ability to proliferate within specific envir-
onments, inducing or repressing specific genes to enhance
growth within the host during infection, thus contributing
to overall pathogenicity (41–43).
IVIAT identification of these Borrelial gene products,
especially antigens from variable regions, during infection
may be utilized to develop enhanced diagnostic methods
(43). The chronic nature of LD and the antigenic
diversity of the spirochetes suggest the spirochete
undergoes dramatic changes in antigenic composition as
it cycles between its arthropod and mammalian hosts and
that this variation plays an important role in immune
detection and destruction. Major proteins or lipoproteins
called variable major protein (VMP) or VMP-like
sequence (VlsE) are responsible for this antigenic varia-
tion strategy evolved to avoid immune detection and
destruction (44, 45).
Furthermore, different membrane surface protein E
(OSPE) enables the spirochete to evade the immune
system and to maintain chronic infection (46–48). In this
multi-peptide ELISA assay based on IVIAT (32–34), we
selected peptides from different components of Borrelia
during specific life cycles, including:
Outer Surface Proteins and Leukocyte
Function Associated Antigen
A prominent late manifestation of B. burgdorferi infec-
tion is Lyme arthritis. Development of antibody reactiv-
ity to outer surface protein A (OspA) occurs towards
the beginning of prolonged arthritic episodes (49).
The progression to an autoimmune state begins with a
cross-reactive response between OspA and a self-antigen,
e.g. leukocyte function associated antigen (LFA).
Identification of a bacterial antigen that displays cross-
reactivity with an autoantigen may provide a model for
development of autoimmune disease induced by
B. Burgdorferi and provide an important antigen to
incorporate into diagnostic methods (50). Outer surface
protein C (OspC) is thought to be an important virulence
factor involved in the transmission and establishment of
early infection (51, 52). Borrelia burgdorferi reduces the
expression of OspC in response to the development of
antibodies, indicating the importance of repressing OspC
expression to avoid clearance and to maintain infection
(53–55). Since humans produce highly specific antibodies
against OspC, measurement of IgG and IgM antibodies
against this highly conserved epitope indicate recent
infection with B. burgdorferi. The Outer surface protein
E (OspE) is expressed in both ticks and mammals, and
elicits a strong antibody response. Specificity of antibody
response with different OspE variants suggests that the
hypervariable regions of OspE are targeted by the
antibody response during infection. Consequently, it is
important to assess the specificity of the antibody
response to OspE epitopes during infection and incorpo-
rate this information into a testing method to target
antibodies to OspE (56).
Immunodominant Antigens
Two peptides, termed C2 and C6, are conserved across
B. burgdorferi sensu lato, B. burgdorferi sensu stricto and
B. garinii (44–47). Antigenicity of these peptides is
supported by the observation that sera from humans,
eCAM 2009;6(3) 285monkeys and mice react with C2 and C6 peptide early
and persistently through the course of infection, indicat-
ing that these peptides contain one or more epitopes that
are broadly antigenic (57).
In a study of human serum samples collected in the
northeast and mid-west of the US, from patients with
acute or chronic LD, 35 of the 41 samples reacted with
and presented significant levels of antibodies against the
C6 peptide. The five serum samples that had no
detectable levels of antibodies against the C6 peptide
were obtained from patients who were in the early stage
of infection (58).
Variable Major Protein
The spirochetes that cause LD express the surface
lipoprotein VMP or VlsE (45). Infection-induced
sequence changes that alter antigenic properties of VlsE
contribute to immune evasion. In an experimental model
a strong VlsE IgG antibody response was apparent by
the fourth week of infection, indicating that VlsE is
expressed during early stage of infection. Serum samples
from LD patients also possessed VlsE antibodies that
were immunoreactive against all species of Borellia (45).
This indicates that there are conserved epitopes among
VlsE variants that are antigenic during infections. Based
on these experiments, researchers employed recombinant
VlsE in an ELISA test and demonstrated diagnostic
sensitivities of 63% for culture-confirmed LD erythema
migrans (EM) cases and 92% for late stage LD infections.
Peptides from Complement Regulator Acquiring
Surface Protein-1 (CRASP-1)
It is well known that the three different genospecies of
B. Burgdorferi exhibit distinct disease manifestations and
tissue tropisms during mammalian infection considering
the ability of pathogenic Borrelia sp. to survive intracel-
lular in the mammalian host, these spirochetes must have
developed efficient strategies for circumventing the innate
immune response (59–61). Along these lines, it has been
suggested that CRASPs are key mediators that allow
B. burgdorferi to evade the innate immune response and
complement-mediated destruction during the acute stage
of infection. Thus CRASP-1 expression is necessary for
B. burgdorferi to resist killing by human serum (59, 61).
Peptides from Decorin Binding Protein for Species-Specific
Serodiagnosis of Lyme Arthritis and Neuroborreliosis
Among individual Borrelial proteins from different
species, sequence heterogeneity varies up to 40%
(62, 64). Decorin binding protein A, a Borrelial outer
surface protein, is one of the key proteins. This antigen
elicits a strong antibody response during experimental
murine borreliosis and has been suggested as a potential
vaccine protein (65). Decorin binding protein-peptide
from B sensu stricto, B. garinii and B. afzelii were
produced and tested as antigens by ELISA.
One hundred percent of patients with neuroborreliosis
(NB) and 93% of patients with Lyme arthritis (LA)
reacted positively. Sera from the majority of patients re-
acted with one rDbpA only and had no or low cross-
reactivity to other variant proteins. In patients with
culture-positive EM, the sensitivity of rDbpA immuno-
globulin G (IgG) or IgM ELISA was low. The DbpA
seems to be a sensitive and specific antigen for the
serodiagnosis of LA or NB, but not of EM (65).
Arthritis-Related Protein or Glutathione-S-Transferase
In addition, a 37-kDa arthritis-related protein of
B. burgdorferi outer-surface protein, termed arthritis-
related protein (Arp), has been shown to prevent or
reduce the severity of arthritis. Antibody responses to this
single protein resembling glutathione-S-Transference were
tested on 124 antibiotic-treated patients with early or late
manifestations of LD (66). Among the 124 antibiotic-
treated patients, 53% with culture-proven EM had IgG
responses to recombinant glutathione S-transferase
(GST)-Arp, as did 59% of the patients with facial palsy
and 68% of those with LA. Therefore, measurement of
antibody against recombinant GST may be additional
tool for detection of B. burgdorferi involvement in
patients with accompanying arthritis during initial
episodes of joint pain or during the maximal period of
arthritis (66).
Antigens from Cross-Reactive Spirochetes and Other
Bacteria
Three genera, Treponema, Borrelia and Leptospira con-
tain pathogenic spirochetes that cause disease in humans.
All spirochetal disease share remarkable similarities in
clinical manifestations including spirochetemia, in the
early stages of the disease, dissemination of spirochetes
to body organs, skin lesions, one or more stages of
the disease are frequently interrupted by a period of
latency, and neurological and cardiac involvement (67).
In addition to similarities of their clinical conditions,
cross-reactivity in all antibody assays including ELISA
and western blot has been observed with treponema and
leptospira (67). This cross-reactivity in an antibody assay
could be related to Borrelia hermsii, which is a cause of
relapsing fever (68), Babesia microti, which causes
Babesiosis (69), Ehrlichia or the agent of human
granulocytic ehrlichiosis (Anaplasma phagocytophilia)
(69, 70) and Bartonella henselae, which can cause Cat-
Scratch disease in a human (71, 72). In addition,
serological cross-reactivity between B. burgdorferi
and bacteria such as a Yersinia enterocolitica outer
membrane protein was shown in a recent study (73).
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have been identified as causative organisms of reactive
arthritis in humans. Cross-reactivity between Yersinia and
B. burgdorferi indicates that molecular mimicry between
bacteria that does not belong to genus Borrelia with B.
burgdorferi is possible (74). This includes other arthro-
genic bacteria such Salmonella and Shigella, which
antibodies against them are detected in 67% of patients
with LD (75). Due to the extensive evidence of cross-
reactivity between Treponema, Leptospira, Babesia,
Ehrlichia, Bartonella and other bacteria that do not
belong to the genus Borrelia, particularly Yersinia with B.
Burgdorferi, the diagnosis of LD should be based on
clinical findings and complete serological analysis of B.
burgdorferi antibodies and the exclusion of its cross-
reactive microorganisms (74, 75). Furthermore, antibo-
dies against these spirochetes may result in autoimmune
and neurological disorders, which are summarized below:
Autoimmunity Induced by Molecular Mimicry of Peptides
from B. burgdorferi and Human Tissue Antigens
Antigenic mimicry of infectious agents and auto-antigens
is a proposed patho-mechanism for autoimmune diseases.
For example, multiple auto-antigen mimotopes of infec-
tion agents (Shigella, Rotavirus and Klebsiella), were
shown to induce autoimmune arthritis and uveitis in rats
(73, 75), multiple microbial peptides (76) and Chlamydia
pneumonia, specific peptides in multiple sclerosis (77, 78),
Campylobacter jejuni in Guillain-Barre Syndrome (79)
and Y. enterocolitica and autoimmune thyroid disease
(80). In this regard spirochete B. burgdorferi could be
another trigger, which is an amino acid sequence
homology with self antigen that may trigger multi-
organ system disorder in genetically predisposed indi-
viduals (80). For example, using a basic local alignment
search (BLAST), four matched with Y. enterocolitica, and
five matched with B. burgdorferi and thyroid stimulating
hormone receptor (TSH-R), up to 50% identity and
similarity were detected. Through this, it was concluded
that Borrelia and Yersinia as environmental triggers can
induce autoimmune thyroid disease in a genetically
predisposed person through molecular mimicry mechan-
isms (80). Another target antigen for autoimmune
reaction downstream of the original bacterial infection
is cytokeratin-10 (81). These auto-antibodies in synovial
lesions of chronic antibiotic treatment-resistant LA are
due to cross-reactivity between cytokratin 10 and a
prominent outer surface protein A of B. burgdorferi (81).
This cross-reactivity suggests a degree of antigenic
mimicry that might contribute toward setting the stage
for autoimmunity, sustaining the response originally
elicited by B. burgdorferi long after elimination of the
spirochete.
This autoimmune reaction in LA may occur through
different mechanism of action and by utilization of
proteases from its mammalian hosts to degrade
extra cellular matrix proteins. Binding of B. burgdorferi
to the host plasminogen and its activator Urokinase, is
able to induce the production of the matrix metallo-
proteinases (MMPs) and degradation of extra cellular
matrix proteins that allows B. burgdorferi to disseminate
in the tissue (82).
This up regulation of MMPs not only plays a role in
dissemination of the organism through extra cellular
matrix tissue, but it can also result in destructive pathology
(83). Among the MMPs that have been suggested
to participate in cartilage degradation in patients with
rheumatoid arthritis are collagenases (MMP-1, -8 and -13),
stromelysins (MMP-3, -10 and -11), and gelatinases
(MMP-2 and -9) (84).
Borrelia burgdorferi is dependent upon the mammalian
or tick host for the provision of amino acids and other
required components. An ABC oligopeptide transporter
system, (OPP) has been well characterized as an
aminopeptidase. This and other proteases fulfill impor-
tant roles in both the basic physiology and pathogenesis
of many microbial pathogens including the ability to
provide required amino acids. These proteases, by
providing required amino acids, enhance the growth of
spirochetes and their motility through mammalian host
tissues (82–84).
Neurological Manifestations of LD
Neurologic involvement in LD occurs in 10–40% of
patients within several weeks to months of the tick bite.
Both the peripheral and the central nervous system
(CNS) can be involved, although disease in the former
occurs more frequently. Early neuroborreliosis manifests
as lymphocytic meningitis (sometimes meningoencephali-
tis), cranial neuropathies and peripheral radiculoneuro-
phathies (85). Patients with meningitis have headaches
and meningeal signs. Examination of the CSF shows a
lymphocytic pleocytosis with normal glucose. There is
often evidence of intrathecal antibody reactive with
B. burgdorferi antigens, and oligoclonal bands may be
present. Direct invasion of B. burgdorferi into the
subarachnoid space with a secondary immune response
is believed to be the cause of meningitis. As with other
manifestations of LD, meningitis can revolve sponta-
neously despite persistent infection (85–87).
Bell’s palsy, due to the involvement of cranial
nerve VII, is the most common cranial neuropathy,
may be bilateral, and is often associated with other
peripheral nervous system manifestations. The most
common peripheral nervous system manifestation is a
mild, patchy, distal sensorimotor (axonal) neuropathy
(86). Neurophysiology testing of individuals with radic-
ular symptoms is abnormal, and in some cases,
lymphocytic pleocytosis in the CSF is demonstrable
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body production (86).
CNS involvement is relatively uncommon, usually late,
and occurs in either of two ways: an acute, disseminated
encephalomyelitis and a more indolent, late, slowly
progressive parenchymal neurologic disorder resembling
multiple sclerosis. Patients with the acute form present
with depressed mental status, cognitive deficits and
multifocal abnormalities on neurologic examination.
Magnetic resonance imaging (MRI) scans of the brain
reveal predominantly white matter lesions, and the CSF
examination can exhibit both lymphocytic pleocytosis
and intrathecal anti-B. burgdorferi antibody production.
These patients respond well to antibiotic therapy with
little, if any, residual deficit (85, 86). In contrast, patients
with slowly progressive inflammatory CNS neuroborre-
liosis have often been misdiagnosed with multiple
sclerosis and have received immunosuppressive treatment
to stabilize their neurologic deficits. These patients have
white matter lesions on brain MRI scans, which had led
to the speculation that this form of neuroborreliosis is a
demyelinating disorder (86).
The presence of decorin binding protein B of
B. burgdorferi and antibody against it has been detected
in cerebrospinal fluid of patients with neurologic LD.
This indicates that B. burgdorferi may enter the CNS
after infection. To infect the brain, the circulating
spirochetes must first cross the blood-brain barrier
(BBB). This barrier is composed of tightly apposed
brain microvascular endothelial cells held together by
that tight junction (87). Several bacteria express their
own proteases that digest the extracellular matrix in order
to invade tissues, but other bacteria, like B. burgdorferi,
appear to utilize the fibrinolytic system of the host to
disseminate (87, 88). Borrelia burgdorferi and Borrelia
crocidurae spirochetes use the fibrinolytic system it
disseminates into host tissues, including the brain. At
the same time B. burgdorferi induces the expression and
secretion of the urokinase-type plasminogen activator
(uPA) and expression of the uPA receptor (uPAR) by a
variety of cell types. As the fibrinolytic system can
directly digest components of the extracellular matrix, it
can also activate other proteases, including MMPs. Not
only do these enzymes naturally occur in the blood
circulation, but they are also expressed as a result of the
interaction between the host cells and B. burgdorferi (89).
To prove the transversal of B. burgdorferi across the
human BBB and systematic endothelial cell barriers
in vitro model systems constructed of human brain
microvascular endothelial cells (BMEC), a human umbili-
cal vein endothelial cell (HUVEC) line where used (90).
Results showed that B. burgdorferi differentially crosses
human BMEC and HUVEC and that the human BMEC
from a barrier to traversal. Importantly, traversal of B.
burgdorferi across human BMEC induces the expression of
plasminogen activators, activator receptors and MMPs.
This fibrinolytic system linked by an activation cascade
may lead to focal and transient degradation of tight
junction proteins that allows B. burgdorferi to invade
CNS (90).
In addition to the activation of the fibrinolytic system,
entry of spirochetes into the CNS may result in a severe
inflammatory reaction, producing proinflammatory cyto-
kines such as interferon-g and TNF-a. The cytokine
reaction with neuronal cells may result in a neural cell
antigen release and entry in circulation and induction of
both cellular and humoral immune reaction against
myelin ganglioside, sulfatides and many other self-
antigens. Therefore, the complementary approach to the
diagnosis and treatment of LD could not be based only
on ELISA, western blot or Multi-Peptide ELISA assay
for detection of antibodies against Borrelia-specific
antigens (32–34), but against other cross-reactive micro-
organisms and different tissue antigens mentioned in this
chapter. Measurements of IgG, IgM and IgA antibodies
against these important antigens that are related to LD
are summarized in Table 2.
Mechanisms by which Tick Salivary Protein-15
Facilitates Bacterial Invasion
The causative spirochete of LD not only employs
means to change antigenic structures, but also
borrows a practical coat from the saliva of its vector,
the Ixodes tick (91, 92). The coating is present on the
many active molecules introduced into the mammalian
host during attachment and feeding. The LD bacterium
replicates and resides in the mid-gut of an infected
tick and moves transiently through the salivary glands
during tick feeding. This transition into the salivary
glands is accompanied by a major phenotypic switch at
the bacterial surface, from expression of OspA to
OspC (91, 92).
Binding of OspC to salivary protein-15 (Salp15) in tick
saliva facilitates bacterial invasion of, and binding to,
salivary glands. This suggests that one function of OspC
is to serve as a ligand for a salivary gland receptor. The
function of Salp15 is to inhibit IgG antibody response to
foreign antigens by halting CD4+ T-Cell activation, and
inducing immune suppression, by binding to a receptor
on the CD4+ T-Cell (91, 92). A direct connection occurs
between CD4+ and C-terminal amino acid residues of
Salp15, allowing for Salp15 to act at the very beginning
of the signaling cascade initiated by T-Cell receptor
binding (92). This Salp15-mediated immunosuppressive
mechanism, along with the activation of the fibrinolytic
system and proinflammatory cytokine production, allows
for facilitated invasion of the host’s immune and CNSs,
as is shown in Fig. 1. This figure shows that after a tick
bite, in addition to B. burgdorferi, tick salivary proteins
enter the host and exert an immunosuppressive effect (A).
288 Novel diagnosis of Lyme diseaseFigure 1. Entry of Borrelia in circulation and different tissue, induction of immuno-suppression with tick salivary protien, activation of the
inflammatory and fibrinolytic systmes, and breaking the blood brain abrrier, which allows invasion of the CNS, resulting in neuroborreliosis.
Table 2. CAM approach for comprehensive measurement of antibodies against Borrelia-specific antigens that are expressed in vitro and in vivo, their
cross-reactive microorganisms and target tissue antigens
Borrelia specific antigens Cross-reactive microorganisms Target tissue antigens or enzymes
B. Burgdorferi lysate Treponema palidum Thyroid stimulating hormone receptor
Outer surface protein-A B. microti Cytokeratin-10
Outer surface protein-C Ehrlichia (Anaplasma phagocytophilia) Plasmin
Outer surface protein-E Bartonella henselae Plasminogen
Leukocyte function associated antigen Y. enterocolitica Collagenase MMPS 1,2,3
VMP immunodominant (C2 peptide) B. hermsii Gelatinase MMPS-9
VMP immunodominant (C6 peptide) Salmonella Urokinase
Variable major protein like sequence Shigella Myosin
Complement regulator-acquiring surface Protein-1 Mycoplasma Collagen
Decorin binding protein of B. burgdorferi sensu stricto Brucella Arthritis related protein
(Glutathione S-transferase)
Decorin binding protein of B. burgdorferi garinii Mycobacteria Myelin basic protein
Decorin binding protein of B. burgdorferi afzelii Leptospira Myelin oligodendrocyte glycoprotein
Chlamydia Pneumonia Ganglioside
Bacterial heat shock protein (HSP-60) a-b-Crystallin
Rota virus Sulfatide
Klebsiella Human heat shock protein-60 (H-HSP-60)
Streptococcal M protein
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B. burgdorferi and protecting it from immune attack
(B). Salp15 could also bind to CD4 on helper cells,
inhibiting TCR ligation-induced-T-cell signaling and
immunosuppression (C). This way the spirochete can
move freely in the circulation and possibly in different
tissues (D). Eventually, immune response to Borrelia and
Salp15 occurs, resulting in antibody as well as proin-
flammatory cytokine production (E). Simultaneously, a
few spirochetes may make contact with the endothelial
cells of the BBB, stimulating expression of plasminogen
activators, plasminogen activator receptors and MMP, all
of which contribute to activation of the fibrinolytic
system (F). This in turn results in focal and transient
degradation of tight junction proteins, allowing
B. burgdorferi to invade the CNS (G). This invasion of
the CNS may result in the destruction of neuronal cells,
the release of neural cell antigens and (H). the production
of antibodies against MBP, MOG, a-B-crystallin and
other neural cell antigens (I). Another possibility for the
production of these antibodies against neural cell anti-
gens is through molecular mimicry between outer surface
protein A (OspA) and neural tissue (93). DNA sequences
of Bb OspA compared with a data bar of DNA
sequences of human neural tissue yielded three sequences
that were identical. The three corresponding Bb peptides
were synthesized, and antibodies were induced against
them. The antibodies cross-reacted with human neural
tissues, including neurons in the human brain, spinal cord
and dorsal root ganglia.
These findings imply that antibodies developed by
LD patients against OspA will also bind to their own
neural tissue, representing a form of autoimmune disease
in which a person’s immune system attacks his own
tissues (93).
CAM Diagnosis and Treatment for LD:
Examples of Patients’ Results
LD is a complex and devastating disorder requiring
efficient means of diagnosis in order to begin treatment
at the onset of infection. We have outlined the method of
transmission and the mechanisms of infection and
maintenance, both of which provide critical information
for developing new diagnostic techniques. During the
various life cycles of Borrelia in the body, the expression
of different antigens is tightly regulated such that the
spirochete may disseminate and survive for long periods
of time. We have shown that the variety of antigens,
identified through IVIAT (43), is integral to accurately
identify infection and indicate the stage of infection.
Information gauged from clinical diagnostic methods
assessing these two components, most easily implemented
into an ELISA method, provides an infection profile
from which an appropriate medical treatment may be
determined. In addition to IVIAT and its use in multi-
peptide ELISA, work is being done to develop a
method to detect immune response to Ixodes proteins
(32–34, 93, 94). Using this novel technology for the
diagnosis of LD, examples of four patients with signs and
symptoms of LD are depicted in Fig. 2. Each specimen
was tested for IgG and IgM antibodies simultaneously
against B. burgdorferi lysate and peptides from outer
surface protein-A (OspA) and OspC, OspE, LFA,
immunodominant peptides (C2+C6), VMP, B. b. sensu
stricto, B. garinii, B. afzelii, Babesia, Ehrlichia, Bartonella,
Treponema palidum, as well as myelin basic protein
(MBP), myelin oligodendrocyte glycoprotein (MOG) and
collagen as tissue antigens.
Note that in Patient 1, despite presentation of clinical
symptomatology of LD, antibodies were not detected
against B. burgdorferi three tested subspecies, antigens
and peptides, Babesia, Ehrlichia, Bartonella, Treponema
or tested target tissue antigens. Since symptoms of
hundreds of other diseases can overlap with those of
LD, the classification of disease should not be based
solely on clinical findings but in conjunction with the
most sensitive laboratory examinations available. For
instance, Patient 2 was classified with Lyme-induced
arthritis, but in this case the diagnosis is confirmed by the
pattern of detected antibodies, particularly against
B. burgdorferi lysate and leukocyte function associated
antigen, as well as very high levels of antibodies against
collagen. In Patient 3, who was classified with neuro-
borreliosis, the diagnosis was also confirmed by the
pattern of detected antibodies against Borrelia antigens
and neuroantigens (MBP and MOG).
Finally, Patient 4, who was classified as having multi-
system organ disorder, reacted strongly with all16
antigens tested in the assay. While patients of this type
with multi-reactive autoantibodies are called universal
reactors, it is plausible that Ig-secreting plasma cells and
memory B cells activated by antigens have undergone
somatic hypermutation and/or class switch recombina-
tion, thereby producing these pathogenic autoantibodies
(95). Indeed, defects in B cell check points have been
shown to be associated with the development of multi-
reactive autoantibodies in patients with systemic lupus
erythematosus or rheumatoid arthritis (96). These four
sample patients’ test results with four different patterns of
reactivity detected only by our novel comprehensive
approach to laboratory examinations justifies CAM
intervention, as summarized in Table 1 with pertinent
references (6–29).
Conclusion
Researchers and practitioners of CAM understand the
necessity for an all-inclusive diagnostic approach and
treatment (as shown in Tables 1 and 2) and can bring
290 Novel diagnosis of Lyme diseaseFigure 2. IgG+IgM measured against 16 different peptides and antigens from Borrelia, cross-reactive microorganisms (Babesia, Ehrlichia,
Bartonella, T. palidum) and target tissue antigens such as myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and collagen.
Index was calculated based on ELISA optical densities of each specimen obtained at 405nm divided by the OD of normal human serum tested
against the same antigen or peptide simultaneously. Note that each patient has a different pattern of antibody reactivity against the sixteen different
tested antigens or peptides.
eCAM 2009;6(3) 291new perspectives and ideas to this developmental
endeavor. Antibodies against Borrelia-specific antigens
and their cross-reactive microorganisms and target
tissue antigens shown in Table 1 can be detected in
blood long before people show symptoms of various
autoimmune disorders. We conclude, therefore, that tests
that can detect these predictive autoantibodies could
warn of the need to take preventive action by CAM
practitioners.
CAM treatment of chronic LD, in addition to a
combination of antibiotics, includes a variety of herbal
and nutritional supplements. These herbal and nutri-
tional supplements provide different intervention strate-
gies for CAM practitioners (Table 2). These actions of
CAM (summarized in Fig. 3) show that different
herbal and nutritional remedies are available to prevent
the binding of tick to skin, to reduce bacterial load by
enhancement of NK cell activity and phagocytosis, to
down-regulate proinflammatory cytokines and inhibit
the fibrinolytic system, and repair the BBB. All of these
improvements can result in elimination of Borrelia from
the tissue and decline in cross-reactive antibodies in
the blood.
This approach, which was recently covered in an article
published in Scientific American, concluded that one day
y-shaped molecules called autoantibodies in a patient’s
blood may tell doctors whether a patient is ‘brewing’
certain diseases and indicate when the onset of symptoms
will occur in the individual (97). Applying this approach,
CAM can make a difference in patients with active or
chronic LD who have been given little hope by
conventional medical doctors. This tailored treatment
for LD by CAM practitioners should be designed
specifically for each patient, based on clinical findings
and laboratory examination for neuroautoimmunity.
In this regard the emphasis should be on immunoregula-
tion and enhancement of cell-mediated immunity (micro-
phage function, NK cell function) and not enhancement
of humoral immunity and antibody production, since
induction of antibody production may actually worsen
Figure 3. Using CAM treatment could prevent different processes ranging from the attachment of the tick to the inflammatory process,
CNS invasion, and the induction of neuroborreliosis. CAM can act through the enhancement of natural killer cell activity, macrophage function,
inhibition of pro-inflammatory cytokine production, inactivation of the fibrinolytic system, and repair of blood brain barriers.
292 Novel diagnosis of Lyme diseasethe autoimmune reaction or autoimmune disease exhib-
ited in many patients with LD.
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